CJC-1295 + Ipamorelin

Why these are combined

CJC-1295 stimulates the hypothalamic-pituitary GHRH pathway; ipamorelin hits the ghrelin receptor without meaningfully raising cortisol or prolactin. Together they pull on two different levers of the same axis. No trial has tested the pairing directly, but the mechanism is well described and this is treated as a standard combo.

Mechanism & pharmacokinetics

The pairing is built around mismatched receptors and mismatched half-lives, both deliberately. CJC-1295 (with DAC) binds serum albumin, which stretches its half-life from minutes to roughly a week, producing a sustained lift in growth-hormone tone via the GHRH receptor. Ipamorelin is short-acting (roughly a 2-hour half-life) and hits the ghrelin receptor (GHS-R) instead, producing a sharp, pulsatile GH release without the cortisol and prolactin increases seen with older GHRPs. Riding a short-acting pulse peptide on top of a long-acting sustained one is meant to approximate the body's natural pulsatile GH release pattern more closely than either compound alone — a pharmacokinetic rationale more than a receptor-interaction one, since GHRH-R and GHS-R signaling converge on GH release without directly competing.

Citations

• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — Dominikowski et al. 2026
• Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — Villegas Meza et al. 2026

Typical community protocol

CJC-1295 typically 100-200 mcg once or twice weekly; ipamorelin 200-300 mcg daily or split into 2-3 smaller doses. Often run in 12-16 week cycles, subcutaneous injection.

Safety notes